Cornea News and Research

RSS

Study to examine the impact of LASIK procedure on patients’ quality of life

The U.S. Food and Drug Administration today announced the launch of a collaborative study with the National Eye Institute and the U.S. Department of Defense to examine the potential impact on quality of life from Laser-Assisted In Situ Keratomileusis (LASIK), a surgical procedure that uses an eximer laser to permanently change the shape of the cornea.

19 Oct 2009

Lions Eye Institute for Transplant & Research to study vision impairment and blindness

Real-time biomedical studies of factors leading to vision impairment are now possible through the world's largest ocular research center at Lions Eye Institute for Transplant & Research.

8 Oct 2009

NEI awards Case Western Reserve $1.57M for bacterial keratitis research

Researchers at Case Western Reserve University School of Medicine have been awarded a $1.57 million renewal grant from the National Eye Institute (NEI) of the National Institutes of Health to continue their study of corneal infections, specifically, bacterial keratitis, associated with contact lens wear. The grant will extend the work initiated last year with the receipt of a $2.4 million, five-year grant from the NEI.

8 Oct 2009

World Sight Day to focus global attention on blindness and vision impairment

World Sight Day, celebrated on October 8th, is an annual day of awareness to focus global attention on blindness and vision impairment as a major public health issue. World Sight Day is coordinated by the International Agency for the Prevention of Blindness (IAPB) under the global initiative of VISION 2020. This year, the theme for World Sight Day is Gender and Eye Health.

8 Oct 2009

Promising alternative to use of live animals for drug testing

International Stem Cell Corporation, the first company to perfect a method of creating human “parthenogenetic” stem cells from unfertilized eggs, announces positive results of its collaboration with Absorption Systems to study ISCO’s stem-cell-derived human corneal tissue as an alternative to live animals for drug testing.

6 Oct 2009

Scientific Advisory Board to provide guidance to support the development of FST-100

Foresight Biotherapeutics announced today the formation of its scientific advisory board to provide guidance to the company for the development of it’s lead product FST-100, a novel formulation of dexamethasone that includes povidone-iodine. Foresight’s Scientific Advisory Board is comprised of leaders in the field of Ophthalmology.

1 Oct 2009

ORBIS' Childhood Blindness Initiative aims to develop 50 pediatric ophthalmology centers across India

ORBIS International's flagship Flying Eye Hospital arrived in Jaipur, India with its international team of volunteer eye care specialists and global sponsor Alcon, Inc. (NYSE: ACL), the world's leading eye care company.

1 Oct 2009

New device for identifying eye conditions in infants

Tell-tale signs of a condition that can blind premature babies are being seen for the first time using a new handheld device in a study at Duke University Medical Center.

22 Sep 2009

Successful eye surgery involves eyetooth implant in eye

Blind for nine years, Sharron “Kay” Thornton has just regained her sight through a first-in-the-U.S. surgical procedure at Bascom Palmer Eye Institute at the University of Miami Miller School of Medicine. The procedure -- modified osteo-odonto-keratoprosthesis (MOOKP) -- implanted her eyetooth in her eye, as a base to hold a prosthetic lens.

17 Sep 2009

FDA approves Sirion's Zirgan for treating acute herpetic keratitis

Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced today that the US Food and Drug Administration (FDA) has approved its New Drug Application for Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% as a treatment for acute herpetic keratitis (dendritic ulcers). The FDA granted orphan drug designation to Zirgan for this indication in April 2007.

17 Sep 2009

AzaSite production increased to combat erythromycin ophthalmic ointment shortage

InSite Vision Incorporated today announced that Inspire Pharmaceuticals, its commercial partner for AzaSite (azithromycin ophthalmic solution) 1% in the U.S and Canada, has committed to increasing production of AzaSite in response to the manufacturing supply shortage of erythromycin ophthalmic ointment (0.5%).

15 Sep 2009

EGCG in green tea helps prolong preservation of stored blood platelets

In two separate studies, a major component in green tea, epigallocatechin-3-O-gallate (EGCG), has been found to help prolong the preservation of both stored blood platelets and cryopreserved skin tissues.

15 Sep 2009

Inspire Pharmaceuticals to increase production of azithromycin ophthalmic solution

Inspire Pharmaceuticals, Inc. announced today that it has been communicating with the U.S. Food and Drug Administration (FDA) and is increasing its production of AzaSite® (azithromycin ophthalmic solution) 1% in response to the manufacturing supply shortage of erythromycin ophthalmic ointment (0.5%).

10 Sep 2009

Presbia unveils implantable micro-lens treatment for presbyopia

Presbia Coöperatief U.A., an early-stage company focused on surgical solutions for presbyopia, today announced that it will unveil a breakthrough implantable micro-lens treatment for presbyopia at the European Society of Cataract and Refractive Surgery Congress (ESCRS) beginning Sept. 12 in Barcelona.

10 Sep 2009

Keratoconus patients to benefit from new contact lens launched by SynergEyes

SynergEyes, Inc., the high Dk hybrid contact lens manufacturer, recently introduced a new advanced lens design for keratoconus patients. ClearKone(TM) is a revolutionary contact lens that takes advantage of the best features of the hybrid platform, providing superior visual acuity, centration, stability, and all-day comfort.

5 Sep 2009

China Sky One Medical submits application to perform clinical trials for two new generic drugs

China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced that the Company has finished the required research for two new generic drugs for eye treatment and submitted application to the State Food and Drug Administration (SFDA) in China to perform clinical trials.

3 Sep 2009

Study reveals that antibiotics used to treat a variety of bacterial infections could cause double vision

Highlights of September's Ophthalmology, the journal of the American Academy of Ophthalmology (Academy), include a 2009 review by the Academy of the safety and efficacy of a widely used corneal transplant procedure and a warning about an unusual but serious reaction to systemic fluoroquinolones, a class of antibiotics used to treat a variety of bacterial infections.

2 Sep 2009

Phase II result reveals effectiveness of GS-101 eye drops at inhibiting corneal neovascularisation

Gene Signal, a company focused on developing innovative drugs to manage angiogenesis based conditions, today announced the publication of interim results from a phase II study suggesting that the antisense oligonucleotide GS-101 (eye drops) is safe and effective at inhibiting and regressing corneal neovascularisation (abnormal new blood vessel growth).

1 Sep 2009

OHSU study reveals that fluoroquinolones may cause double vision

Highlights of September's Ophthalmology, the journal of the American Academy of Ophthalmology (Academy), include a 2009 review by the Academy of the safety and efficacy of a widely used corneal transplant procedure and a warning about an unusual but serious reaction to systemic fluroquinolones, a class of antibiotics used to treat a variety of bacterial infections.

1 Sep 2009

Phase 2 clinical study of Resolvin RX-10045 for dry eye syndrome provides positive data

Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced positive data from a Phase 2 clinical study evaluating RX-10045, a resolvin administered as a topical eye drop for the treatment of patients with chronic dry eye syndrome.

24 Aug 2009

Cornea News and Research

Study to examine the impact of LASIK procedure on patients’ quality of life

Lions Eye Institute for Transplant & Research to study vision impairment and blindness

NEI awards Case Western Reserve $1.57M for bacterial keratitis research

World Sight Day to focus global attention on blindness and vision impairment

Promising alternative to use of live animals for drug testing

Scientific Advisory Board to provide guidance to support the development of FST-100

ORBIS' Childhood Blindness Initiative aims to develop 50 pediatric ophthalmology centers across India

New device for identifying eye conditions in infants

Successful eye surgery involves eyetooth implant in eye

FDA approves Sirion's Zirgan for treating acute herpetic keratitis

AzaSite production increased to combat erythromycin ophthalmic ointment shortage

EGCG in green tea helps prolong preservation of stored blood platelets

Inspire Pharmaceuticals to increase production of azithromycin ophthalmic solution

Presbia unveils implantable micro-lens treatment for presbyopia

Keratoconus patients to benefit from new contact lens launched by SynergEyes

China Sky One Medical submits application to perform clinical trials for two new generic drugs

Study reveals that antibiotics used to treat a variety of bacterial infections could cause double vision

Phase II result reveals effectiveness of GS-101 eye drops at inhibiting corneal neovascularisation

OHSU study reveals that fluoroquinolones may cause double vision

Phase 2 clinical study of Resolvin RX-10045 for dry eye syndrome provides positive data

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News